Solifenacin Direct Compression via Antioxidant and Binder
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Solifenacin, a compound with excellent selective antagonistic action against muscarinic M3 receptors, faces challenges in stability during the manufacturing process due to decomposition issues, particularly during wet granulation, where it is sensitive to water and excipients, making it difficult to achieve content uniformity and stability in commercial production.
Innovation Solution
A solifenacin preparation comprising solifenacin or its pharmaceutically acceptable salt, an antioxidant (such as butylhydroxytoluene), and a binder (like low-substituted hydroxypropyl cellulose) is developed, allowing for direct compression instead of wet granulation, which stabilizes the compound and ensures content uniformity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If wet granulation process is used to manufacture solifenacin formulation, then content uniformity is improved, but drug stability deteriorates due to decomposition and amorphous form generation
Solution Approach 1:
The patent changes the physical-chemical parameters of the formulation by incorporating excipients with specific properties (superdisintegrant with low water solubility, binder with specific Tg range) to control the crystalline state of solifenacin and prevent amorphous form generation during wet granulation, thereby maintaining drug stability while achieving content uniformity
Solution Approach 2:
The patent creates a composite formulation system combining solifenacin with specific excipients (superdisintegrant, binder, lubricant) that work synergistically to maintain drug stability during processing. The composite material approach allows the formulation to achieve both content uniformity through wet granulation and stability through controlled crystalline structure
2Stability of the object's composition
If water content is controlled during manufacturing to prevent amorphous form, then drug stability is improved, but manufacturing complexity increases due to sensitive process conditions
Solution Approach 1:
The patent establishes specific parameter ranges for manufacturing conditions (water content 2-10%, binder Tg 150-250°C, superdisintegrant content 5-20%) that provide a robust process window. These parameter specifications simplify manufacturing by defining clear operational boundaries that ensure drug stability without requiring excessive process control complexity
3Stability of the object's composition
If polyethylene oxide binder is used to prevent amorphization, then drug stability is improved, but compatibility issues arise with oxidants and other excipients
Solution Approach 1:
The patent introduces a superdisintegrant as a key intermediary component that mediates between the drug and binder, preventing direct harmful interactions. The superdisintegrant with specific properties (low water solubility, specific particle size) acts as a protective intermediary that maintains drug stability while improving compatibility with various excipients including oxidants
Solution Approach 2:
The patent specifies a Tg range (150-250°C) for the binder that excludes polyethylene oxide (Tg < 100°C) but includes compatible binders like HPMC and PVP. This parameter-based selection criterion ensures excipient compatibility while maintaining the ability to prevent amorphization and ensure drug stability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The addition of an antioxidant and binder in the solifenacin preparation significantly reduces degradation products, achieves content uniformity, and provides a dissolution pattern equivalent to commercial products, enhancing stability and manufacturing efficiency.
Implementation Method 1
an amorphous form of solifenacin succinate is generated during the process of wet granulation and easily oxidized within a short period
Implementation Method 2
the cohesiveness of solifenacin or a pharmaceutically acceptable salt thereof complicates the formulation process
Data Source
AI summary
The present invention relates to a solifenacin preparation containing solifenacin or a pharmaceutically acceptable salt thereof, an antioxidant, and a binder, which is manufactured via direct compression. Compared to the preparations manufactured via conventional wet granulation process, the preparation of the present invention can be manufactured by a simplified process such as direct compression, and has improved content uniformity, mixing degree, etc., even when the preparation is manufactured by high speed tableting.